1
|
Reddoch-Cardenas KM, Perez SL, Ferdin JN, Meledeo MA. Evaluation of platelets componentized with the Reveos Automated Blood Processing System and stored for 7 days at room temperature in a non-Di(2-ethylhexyl) phthalate (DEHP) platelet pooling set. Transfusion 2024; 64 Suppl 2:S146-S154. [PMID: 38491915 DOI: 10.1111/trf.17780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 02/29/2024] [Accepted: 03/01/2024] [Indexed: 03/18/2024]
Abstract
BACKGROUND Platelet concentrates (PCs) used for transfusion can be produced by apheresis or derived from whole blood (WB). The Reveos device is the first US Food and Drug Administration-approved automated blood processing system that can produce PCs. In this work, we evaluated the quality and function of Reveos-collected PCs stored for 7 days at room temperature. STUDY DESIGN AND METHODS WB was collected from healthy donors and componentized on the day of collection (Fresh) or after an overnight hold (Overnight). PCs were produced (n = 7 Fresh; n = 6 Overnight), stored at room temperature in plasma, and evaluated on days 1 and 7 for quality metrics, platelet activation, clot formation, and aggregation response. RESULTS Platelet count was comparable between Fresh and Overnight PCs. A drop in pH was reported in Fresh day 7 PCs (p < .001, vs. day 1) but not in Overnight. Overnight units displayed the lowest levels of P-selectin expression (p = .0008, vs. day 7 Fresh). Reduced clot strength and increased lysis were observed in both Fresh and Overnight units on day 7 (vs. day 1). Overnight-hold PCs resulted in the highest clot strength on day 7 (p = .0084, vs. Fresh). No differences in aggregation were reported between groups. CONCLUSION Reveos-processed PCs produced from overnight-hold WB performed better in hemostatic function assays and displayed reduced activation compared to fresh WB-derived PCs, although both PC groups maintained platelet quality throughout storage. Utilization of overnight WB for PC preparation with Reveos holds promise as an alternative method of producing platelets for transfusion purposes.
Collapse
Affiliation(s)
- Kristin M Reddoch-Cardenas
- Blood and Shock Resuscitation, U.S. Army Institute of Surgical Research, JBSA-FT, Sam Houston, Texas, USA
| | - Samantha L Perez
- Blood and Shock Resuscitation, U.S. Army Institute of Surgical Research, JBSA-FT, Sam Houston, Texas, USA
| | - Justin N Ferdin
- Blood and Shock Resuscitation, U.S. Army Institute of Surgical Research, JBSA-FT, Sam Houston, Texas, USA
| | - Michael A Meledeo
- Blood and Shock Resuscitation, U.S. Army Institute of Surgical Research, JBSA-FT, Sam Houston, Texas, USA
| |
Collapse
|
2
|
Cid J, Comasòlivas N, Pérez-Aliaga A, Illingworth N, Cardoso M. Comparison of automated versus semi-automated whole blood processing systems: A systematic review. Vox Sang 2023; 118:263-271. [PMID: 36626280 DOI: 10.1111/vox.13400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 12/22/2022] [Accepted: 12/22/2022] [Indexed: 01/11/2023]
Abstract
BACKGROUND AND OBJECTIVES Implementation of automated steps in preparing blood components for transfusion from whole blood collections has produced improvements in multiple fields. The aim of this review is to summarize data from existing literature related to automation of whole blood processing systems. MATERIALS AND METHODS We searched MEDLINE for studies comparing semi-automated and fully automated whole blood processing systems published before 20 July 2021. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Additionally, we performed a manual search. RESULTS We identified 500 studies, of which 459 (92%) did not meet the eligibility criteria, and finally 17 studies were included in the analysis. Manual search included six additional studies. Publication year ranged from 2004 to 2021. Automation reduced the run-time (from 92 to 76 min), improved recovery of haemoglobin in red cell concentrates (RCCs) and resulted in higher red blood cell and platelet yields. Automation also reduced discard rates due to whole blood bag ruptures (1.2%-0.1%), low volume of RCCs (<200 ml; 0.5%-0.03%) and haemolytic plasma (2.1%-0.6%). Automation could reduce the number of full-time equivalent (FTE) operators or maintain the number of FTE operators while performing additional procedures, and it reduced to 1.13 m2 the space required for the device. CONCLUSION Automation of whole blood processing resulted in continued improvements in productivity, product quality and technical features. However, too few publications are available to reach strong conclusions. Therefore, it is necessary to expand the scientific knowledge in this field.
Collapse
Affiliation(s)
- Joan Cid
- Apheresis and Cell Therapy Unit, Department of Hematology and Hemotherapy, ICMHO, IDIBAPS, Clínic Barcelona, University of Barcelona, Barcelona, Spain
| | - Nil Comasòlivas
- Terumo Blood and Cell Technologies, Inc., Denver, Colorado, USA
| | | | | | - Marcia Cardoso
- Terumo Blood and Cell Technologies, Inc., Denver, Colorado, USA
| |
Collapse
|
3
|
Tynngård N, Alshamari A, Månsson F, Ramström S. Variation in activation marker expression within the platelet population - a new parameter for evaluation of platelet flow cytometry data. Platelets 2022; 33:1113-1118. [PMID: 35848430 DOI: 10.1080/09537104.2022.2078490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
In flow cytometry, individual cells are investigated. Platelet activation is normally reported in form of percentage of platelets expressing the marker (positive platelets) and/or mean/median fluorescence intensity (MFI) for the entire analyzed population. None of these take into account the variance of the marker expression between individual platelets. This can be obtained as data on coefficient of variation (CV). This study explores if CV provides additional information regarding platelet function. Samples from platelet concentrates (PCs) prepared by apheresis- (n = 13) and interim platelet unit (IPU) technique (n = 26) and stored for 6-7 days were included and compared. Spontaneous- and agonist-induced expression of activation markers (fibrinogen binding and exposure of P-selectin, LAMP-1, and CD63) was investigated as percentage positive platelets, MFI and CV. Spontaneous expression of P-selectin as percentage positive platelets and MFI was higher for IPU PCs than apheresis PCs, which in contrast had higher agonist-induced activation. CV for spontaneous fibrinogen binding and P-selectin exposure was larger for apheresis PCs, while IPU PCs generally had larger CV for P-selectin, LAMP-1, and CD63 after agonist stimulation. Our findings show that CV adds additional information when assessing platelet activation by providing data on the variation in activation responses within the platelet population.
Collapse
Affiliation(s)
- Nahreen Tynngård
- Department of Clinical Immunology and Transfusion Medicine, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.,Research and Development Unit in Region Östergötland and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
| | - Aseel Alshamari
- Department of Clinical Immunology and Transfusion Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.,Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
| | - Freja Månsson
- Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
| | - Sofia Ramström
- Cardiovascular Research Centre, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.,Department of Clinical Chemistry and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
| |
Collapse
|
4
|
Selby R, Duffy ER, Berny-Lang MA, Andry CD, Lee AYY. Impact of specific preclinical variables on coagulation biomarkers in cancer-associated thrombosis. Thromb Res 2021; 191 Suppl 1:S26-S30. [PMID: 32736774 DOI: 10.1016/s0049-3848(20)30393-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Revised: 11/18/2019] [Accepted: 11/24/2019] [Indexed: 10/23/2022]
Abstract
Coagulation biomarkers are being actively studied for their diagnostic and prognostic value in patients with venous thromboembolism and cancer, as well as in the study of pathogenic mechanisms between cancer and thrombosis. For the results of such studies to be accurate and reproducible, attention must be paid to minimize sources of error in all phases of testing. The pre-analytical phase of laboratory testing is known to be fraught with the majority of errors. Coagulation testing is particularly susceptible to conditions during collection, processing, transport and storage of specimens which can lead to clinically significant errors in results. In addition, changes in pre-analytical conditions can impact different biomarkers differently. Therefore, research studies investigating coagulation biomarkers must carefully standardize not just the analytical phase, but also the pre-analytical phase of testing to ensure accuracy and reliability. We briefly review the impact of pre-analytical conditions on coagulation testing in general, and on specific biomarkers in cancer and thrombosis. In addition, we provide recommendations to reduce pre-analytical errors by developing and sharing standard operating procedures that specifically target standardization of methodologies for collecting specimens and measuring current and emerging coagulation biomarkers in cancer studies.
Collapse
Affiliation(s)
- Rita Selby
- Departments of Laboratory Medicine and Pathobiology & Medicine, University of Toronto, Toronto, ON, Canada
| | - Elizabeth R Duffy
- Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
| | - Michelle A Berny-Lang
- Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Christopher D Andry
- Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
| | - Agnes Y Y Lee
- University of British Columbia, British Columbia Cancer Agency, Vancouver, BC, Canada.
| |
Collapse
|
5
|
Malvaux N, Schuhmacher A, Defraigne F, Jacob R, Bah A, Cardoso M. Remodelling whole blood processing through automation and pathogen reduction technology at the Luxembourg Red Cross. Transfus Apher Sci 2021; 60:103195. [PMID: 34147359 DOI: 10.1016/j.transci.2021.103195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 06/02/2021] [Accepted: 06/11/2021] [Indexed: 11/26/2022]
Abstract
In 2014-2015, the Luxembourg Red Cross (LRC) implemented a fully automated system (FAS) able to process 4 whole blood units simultaneously, and a pathogen reduction technology (PRT) based on riboflavin and ultraviolet light to improve safety of platelet concentrates (PCs). In this observational study, the impact of both technologies to enable this centralised blood transfusion centre to provide safe and timely blood components supply for the whole country was analysed. Standard quality control parameters for blood components, productivity and safety were compared from data collected with the conventional semi- automated buffy coat method and with FAS/PRT. The FAS decreased processing time when compared with the buffy coat method and facilitated the daily routine at the LRC. Red blood cell concentrates, plasma units and PCs prepared with both methods were conform to the European Directorate for the Quality of Medicines & HealthCare specifications. PCs prepared by FAS showed high yields, with decreased variability when the device-related software (T-Pool Select) was used. PRT had minimal impact on platelet yields and product quality and induced no increase in transfusion reaction notifications. The FAS and PRT transformed the daily routine of blood component manufacture by allowing increased productivity and efficiency, notwithstanding resource containment and without impacting quality, yet promoting safety.
Collapse
Affiliation(s)
- Nicolas Malvaux
- Luxembourg Red Cross, Boulevard Joseph II 42, L-1840, Luxembourg.
| | - Anne Schuhmacher
- Luxembourg Red Cross, Boulevard Joseph II 42, L-1840, Luxembourg.
| | | | - Remy Jacob
- Luxembourg Red Cross, Boulevard Joseph II 42, L-1840, Luxembourg.
| | - Aicha Bah
- Terumo BCT Europe, Ikaroslaan 41, 1930 Zaventem, Belgium.
| | - Marcia Cardoso
- Terumo BCT Europe, Ikaroslaan 41, 1930 Zaventem, Belgium.
| |
Collapse
|
6
|
Blood repellent superhydrophobic surfaces constructed from nanoparticle-free and biocompatible materials. Colloids Surf B Biointerfaces 2021; 205:111864. [PMID: 34049000 DOI: 10.1016/j.colsurfb.2021.111864] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2020] [Revised: 05/08/2021] [Accepted: 05/18/2021] [Indexed: 02/06/2023]
Abstract
Durable and environment friendly superhydrophobic surfaces are needed for a set of important applications. Biomedical applications, in particular, impose stringent requirements on the biocompatibility of the materials used in the fabrication of superhydrophobic surfaces. In this study, we demonstrate the fabrication of mechanically durable superhydrophobic surfaces via an in-situ structuring strategy starting from natural carnauba wax and biocompatible polydimethylsiloxane (PDMS) materials. The transfer of the structure of the paper to a free-standing PDMS film provided the microscale structure. On top of this structured surface, the wax was spray-coated, initially resulting in a relatively homogeneous film with limited liquid repellence. The key in achieving superhydrophobicity was rubbing the surface for in-situ generation of a finely textured wax coating with a water contact angle of 169° and a sliding angle of 3°. The hierarchically structured surface exhibits mechanical robustness as demonstrated with water impact and linear abrasion tests. We finally demonstrate repellence of the surfaces against a range of blood products including platelet suspension, erythrocyte suspension, fresh plasma, and whole blood.
Collapse
|
7
|
Gammon RR, Devine D, Katz LM, Quinley E, Wu Y, Rowe K, Razatos A, Min K, Reichenberg S, Smith R. Buffy coat platelets coming to America: Are we ready? Transfusion 2020; 61:627-633. [PMID: 33174258 DOI: 10.1111/trf.16184] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 09/21/2020] [Accepted: 09/22/2020] [Indexed: 01/05/2023]
Abstract
BACKGROUND Buffy coat (BC) platelets (PLTs) have been used globally for many years. In 2004 Canadian Blood Services (CBS) made the decision to transition from PLT-rich plasma (PRP) to BC PLTs. We reviewed the benefits and manufacture process of BC and the implementation challenges involved. STUDY DESIGN AND METHODS A literature review was performed in the following areas: BC efficacy, donor population shifts, production and good stewardship of PLTs, logistic considerations with overnight holds, advantages of the overnight hold, the CBS experience, licensure and standards, and changes needed to produce BC PLTs in the United States. The aim was to analyze current practice and identify possible actions for blood centers and hospitals. RESULTS Implementation of BC would offer an additional source of PLTs to address the growing elderly population and the declining apheresis donor base. Substantial logistic, operational, and financial benefits were seen when CBS transitioned to BC with overnight hold. CONCLUSIONS Buffy coat blood products are widely used throughout the world. Recent conversion from PRP to BC by CBS showed that conversion can be accomplished with planning, communication, and partnership from all stakeholders. In conclusion, BC PLTs are worth serious consideration in the United States, but regulatory barriers in the United States will need to be addressed.
Collapse
Affiliation(s)
| | - Dana Devine
- Canadian Blood Services and University of British Columbia, Vancouver, British Columbia, Canada
| | - Louis M Katz
- Mississippi Valley Regional Blood Center, Davenport Iowa and University of Iowa Carver College of Medicine, Iowa City, Iowa
| | - Eva Quinley
- Independent Contractor, Knoxville, Tennessee
| | - YanYun Wu
- University of Miami, Coral Gables, Florida
| | | | | | | | | | | |
Collapse
|
8
|
Ravanat C, Dupuis A, Marpaux N, Naegelen C, Mourey G, Isola H, Laforêt M, Morel P, Gachet C. In vitro
quality of amotosalen‐
UVA
pathogen‐inactivated mini‐pool plasma prepared from whole blood stored overnight. Vox Sang 2018; 113:622-631. [DOI: 10.1111/vox.12697] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Revised: 06/26/2018] [Accepted: 06/28/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Catherine Ravanat
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| | - Arnaud Dupuis
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| | | | | | - Guillaume Mourey
- EFS Bourgogne‐Franche‐Comté UMR1098 Besançon France
- Université Bourgogne Franche Comté INSERM EFS Bourgogne‐Franche‐Comté UMR1098 Besançon France
| | - Herve Isola
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| | - Michel Laforêt
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| | - Pascal Morel
- EFS Bourgogne‐Franche‐Comté UMR1098 Besançon France
- Université Bourgogne Franche Comté INSERM EFS Bourgogne‐Franche‐Comté UMR1098 Besançon France
| | - Christian Gachet
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| |
Collapse
|
9
|
Singh S, Shams Hakimi C, Jeppsson A, Hesse C. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates. Transfus Apher Sci 2017; 56:870-874. [PMID: 29126740 DOI: 10.1016/j.transci.2017.10.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 10/12/2017] [Accepted: 10/16/2017] [Indexed: 11/25/2022]
Abstract
Platelet storage lesion is characterized by morphological changes and impaired platelet function. The collection method and storage medium may influence the magnitude of the storage lesion. The aim of this study was to compare the newly introduced interim platelet unit (IPU) platelet concentrates (PCs) (additive solution SSP+, 40% residual plasma content) with the more established buffy-coat PCs (SSP, 20% residual plasma content) and apheresis PCs (autologous plasma) in terms of platelet storage lesions. Thirty PCs (n=10 for each type) were assessed by measuring metabolic parameters (lactate, glucose, and pH), platelet activation markers, and in vitro platelet aggregability on days 1, 4, and 7 after donation. The expression of platelet activation markers CD62p (P-selectin), CD63 (LAMP-3), and phosphatidylserine was measured using flow cytometry and in vitro aggregability was measured with multiple electrode aggregometry. Higher platelet activation and lower in vitro aggregability was observed in IPU than in buffy-coat PCs on day 1 after donation. In contrast, metabolic parameters, expression of platelet activation markers, and in vitro aggregability were better maintained in IPU than in buffy-coat PCs at the end of the storage period. Compared to apheresis PCs, IPU PCs had higher expression of activation markers and lower in vitro aggregability throughout storage. In conclusion, the results indicate that there are significant differences in platelet storage lesions between IPU, buffy-coat, and apheresis PCs. The quality of IPU PCs appears to be at least comparable to buffy-coat preparations. Further studies are required to distinguish the effect of the preparation methods from storage conditions.
Collapse
Affiliation(s)
- Sukhi Singh
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Caroline Shams Hakimi
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Anders Jeppsson
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Camilla Hesse
- Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Regional Blood Bank, Sahlgrenska University Hospital, Gothenburg, Sweden.
| |
Collapse
|
10
|
van der Meer PF, Couture C, Hervig T, Kruit G, Devine DV, de Korte D, Kerkhoffs JL. Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres. Vox Sang 2016; 112:9-17. [DOI: 10.1111/vox.12465] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Revised: 09/15/2016] [Accepted: 09/17/2016] [Indexed: 11/28/2022]
Affiliation(s)
- P. F. van der Meer
- Department of Product and Process Development; Sanquin Blood Bank; Amsterdam The Netherlands
- Department of Clinical Transfusion Research; Sanquin Research; Leiden The Netherlands
| | - C. Couture
- Canadian Blood Services; Ottawa ON Canada
| | - T. Hervig
- Department of Immunology and Transfusion Medicine; Haukeland University Hospital; Bergen Norway
| | - G. Kruit
- Department of Production; Sanquin Blood Bank; Amsterdam The Netherlands
| | | | - D. de Korte
- Department of Product and Process Development; Sanquin Blood Bank; Amsterdam The Netherlands
| | - J.-L. Kerkhoffs
- Department of Clinical Transfusion Research; Sanquin Research; Leiden The Netherlands
- Department of Hematology; Haga Teaching Hospital; The Hague The Netherlands
| |
Collapse
|
11
|
Begue S, Morel P, Djoudi R. [Innovative technology and blood safety]. Transfus Clin Biol 2016; 23:245-252. [PMID: 27616610 DOI: 10.1016/j.tracli.2016.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2016] [Accepted: 07/19/2016] [Indexed: 11/17/2022]
Abstract
If technological innovations are not enough alone to improve blood safety, their contributions for several decades in blood transfusion are major. The improvement of blood donation (new apheresis devices, RFID) or blood components (additive solutions, pathogen reduction technology, automated processing of platelets concentrates) or manufacturing process of these products (by automated processing of whole blood), all these steps where technological innovations were implemented, lead us to better traceability, more efficient processes, quality improvement of blood products and therefore increased blood safety for blood donors and patients. If we are on the threshold of a great change with the progress of pathogen reduction technology (for whole blood and red blood cells), we hope to see production of ex vivo red blood cells or platelets who are real and who open new conceptual paths on blood safety.
Collapse
Affiliation(s)
- S Begue
- Direction médicale, établissement français du sang, 20, avenue du Stade-de-France, 93218 La Plaine-Stade-de-France, France
| | - P Morel
- Établissement français du sang - Bourgogne-Franche Comté, 8, rue du Docteur-Jean-François-Xavier-Girod, 25000 Besançon, France
| | - R Djoudi
- Établissement français du sang - Île-de-France, 122/130, rue Marcel-Hartmann, LEAPARK bâtiment A, 94200 Ivry-sur-Seine, France.
| |
Collapse
|
12
|
van der Meer PF, de Korte D. The Effect of Holding Times of Whole Blood and Its Components During Processing on In Vitro and In Vivo Quality. Transfus Med Rev 2015; 29:24-34. [DOI: 10.1016/j.tmrv.2014.10.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2014] [Revised: 10/14/2014] [Accepted: 10/17/2014] [Indexed: 11/25/2022]
|
13
|
Lotens A, Najdovski T, Cellier N, Ernotte B, Lambermont M, Rapaille A. New approach to 'top-and-bottom' whole blood separation using the multiunit TACSI WB system: quality of blood components. Vox Sang 2014; 107:261-8. [PMID: 24861237 DOI: 10.1111/vox.12159] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2013] [Revised: 04/24/2014] [Accepted: 04/25/2014] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND OBJECTIVES TACSI whole blood system is designed to combine primary and secondary processing of six whole blood bags into plasma units, buffy coat and red blood cell concentrates. The aim of this study was to investigate the specifications and in vitro storage parameters of blood components compared with standard centrifugation and separation processing. MATERIALS AND METHODS Whole blood bags, collected in CRC kits, were treated on a TACSI whole blood system. They were compared with whole blood bags collected in Composelect kits. In addition to routine quality control analyses, conservation studies were performed on red blood cell concentrates for 42 days and on plasma for 6 months. Platelets pools with five buffy coats were also created, and cellular contamination was evaluated. RESULTS Red blood cell concentrates produced from TACSI whole blood met European quality requirements. For white blood cell count, one individual result exceeded 1 × 10(6) cells/unit. All plasma units fell within specifications for residual cellular contamination and storage parameters. The performances of the TACSI whole blood system allow for the preparation of low volume buffy coats with a recovery of 90% of whole blood platelets. Haemoglobin losses in TACSI BC are smaller, but this did not result in higher haemoglobin content of red cells. These BC are suitable for the production of platelet concentrates. CONCLUSION From these in vitro data, red blood cell concentrates produced using TACSI whole blood are suitable for clinical use with a quality at least equivalent to the control group.
Collapse
Affiliation(s)
- A Lotens
- Service du Sang, Croix-Rouge de Belgique, Suarlée, Belgium
| | | | | | | | | | | |
Collapse
|
14
|
Bontekoe IJ, van der Meer PF, Mast G, de Korte D. Separation of centrifuged whole blood and pooled buffy coats using the new CompoMat G5: 3 years experience. Vox Sang 2014; 107:140-7. [PMID: 24602034 DOI: 10.1111/vox.12140] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2013] [Revised: 01/28/2014] [Accepted: 02/03/2014] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND OBJECTIVES Semi-automatic separation devices can be used for the separation of centrifuged whole blood into leucoreduced red cell concentrate (LR-RCC), plasma and buffy coat (BC) and to make platelet concentrates (PC) from pooled BCs. To improve and to obtain a more uniform and standardized process, the CompoMat G5 (Fresenius) was implemented, a new-generation semi-automated device. MATERIALS AND METHODS Uniform programs for WB separation and preparation of PCs were validated, using collection and pooling systems with CompoFlow (CF) closures, which can be automatically opened by the G5. Cell counts were performed and compared with historic data of blood components obtained with the formerly used Compomat G4 and Optipress II. After implementation, different adjustments were made to improve product quality. RESULTS Leucoreduced red cell concentrates (280 ± 15 ml, 53 ± 5 g haemoglobin) and plasma (317 ± 16 ml) met European guidelines. BCs (48 ± 2 ml, 0·42 ± 0·05 l/l, 93 ± 25 × 10(9) platelets) contained a similar platelet (PLT) content as BC prepared before with the Compomat G4. A relatively high percentage (4-6%) of PCs (330 ± 17 ml, 330 ± 50 × 10(9) PLT, 0·12 ± 0·21 × 10(6) leucocytes) contained <250 × 10(9) PLT which was the subject of improvement studies. After implementation, RCC and BC discard decreased and workload was less. Operator complaints were also less frequent. CONCLUSION The same high-quality blood components can be prepared by using the CompoMat G5 as previously with other semi-automated devices. Improvement was realized by automation of the opening process by the use of collection systems with CF closures, which led to a decrease in discarded units and workload.
Collapse
Affiliation(s)
- I J Bontekoe
- Department of Product and Process Development, Amsterdam, the Netherlands
| | | | | | | |
Collapse
|
15
|
Cid J, Magnano L, Lozano M. Automation of blood component preparation from whole blood collections. Vox Sang 2014; 107:10-8. [DOI: 10.1111/vox.12131] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Revised: 11/08/2013] [Accepted: 11/08/2013] [Indexed: 11/26/2022]
Affiliation(s)
- J. Cid
- Department of Hemotherapy and Hemostasis; Hospital Clínic; IDIBAPS; Barcelona Spain
| | - L. Magnano
- Department of Hemotherapy and Hemostasis; Hospital Clínic; IDIBAPS; Barcelona Spain
| | - M. Lozano
- Department of Hemotherapy and Hemostasis; Hospital Clínic; IDIBAPS; Barcelona Spain
| |
Collapse
|
16
|
Johnson L, Winter KM, Kwok M, Reid S, Marks DC. Evaluation of the quality of blood components prepared using the Reveos automated blood processing system. Vox Sang 2013; 105:225-35. [DOI: 10.1111/vox.12051] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2013] [Revised: 04/05/2013] [Accepted: 04/07/2013] [Indexed: 01/03/2023]
Affiliation(s)
- L. Johnson
- Applied and Developmental Research; Research and Development; Australian Red Cross Blood Service; Sydney; Australia
| | - K. M. Winter
- Applied and Developmental Research; Research and Development; Australian Red Cross Blood Service; Sydney; Australia
| | - M. Kwok
- Applied and Developmental Research; Research and Development; Australian Red Cross Blood Service; Sydney; Australia
| | - S. Reid
- Applied and Developmental Research; Research and Development; Australian Red Cross Blood Service; Sydney; Australia
| | - D. C. Marks
- Applied and Developmental Research; Research and Development; Australian Red Cross Blood Service; Sydney; Australia
| |
Collapse
|